Increased food allergy and vitamin D: Randomized, double‐blind, placebo‐controlled trial

Pediatrics International

Feb 2014

Citations: 66

Influential: 1

Interventional (Human) Studies

What this study found

Vitamin D3 did not improve the primary eczema outcome, and it did not reduce atopic dermatitis through 2 years. At 3 months, SCORAD was 4.75 ± 7.49 in the vitamin D3 group versus 3.95 ± 5.36 in the placebo group, with no significant difference. By age 2 years, food allergy was higher with vitamin D3: 10/39 (25.6) versus 3/40 (7.5), RR 3.42, 95%CI 1.02-11.77, P = 0.030. At least one allergic condition was also more common: 17/39 (43.6) versus 7/40 (17.5), RR 2.49, 95%CI 1.16-5.34, P = 0.012. No serious adverse events were reported.

Study & population: Randomized, double-blind, placebo-controlled trial in Japan.
Intervention: Mothers in the active arm received oral vitamin D3 (StatusD3®) at 800 IU/day, given as four 200 IU tablets once daily for 6 weeks during lactation.
Key limitation: Substantial loss to follow-up limited interpretability, and the analyzed outcome samples were small.

View source

Open PDF

Original abstract

To elucidate whether maternal vitamin D supplementation during lactation improves infantile eczema and other subsequent allergic disorders, a randomized, double‐blind, placebo‐controlled trial was performed.